• MedTech and Biotech Deals Update – 15 Sep

    Good morning. Some big deals news from medtech and biotech this week. Here are the top headlines I found. News comes from molecular glues, surgical robotics, mitochondria, women’s health and more. Congratulations to everyone involved.

    🔔 Novartis has stuck on a second deal to its partnership with molecular glue degrader biotech Monte Rosa Therapeutics that includes a $120 million upfront payment.

    🔔ViCentra, a medical device company based in Utrecht, Netherlands, has raised €72.4 million in series D funding to scale up production and launch its Kaleido 2 insulin patch pump in Europe.

    🔔U.S. nonprofit Wellcome Leap is partnering with the Melinda French Gates-founded coalition Pivotal, raising $100 million to advance women’s health research in areas with the highest need.

    đź””Despite the stagnant biotech IPO market of the last six months, LB Pharmaceuticals has set out plans to reel in hundreds of millions of dollars through its upcoming public debut.

    đź””The Chinese minimally invasive robot developer Ronovo Surgical announced it has raised $67 million to expand the commercial reach of its system within the country, with a helping hand from Johnson & Johnson.

    🔔Investors Bet $235 Million on Bringing AI to Scientific Research. Lila Sciences, which uses AI to develop novel drugs and materials, has received fresh funding led by Collective Global and Braidwell.

    đź””Edwards Lifesciences has fully acquired Vectorious Medical Technologies Ltd. for $497 million, following a series of investments in the heart failure technology company over the last five years.

    đź””Trinity College spin-out ProVerum secures $80 million in funding to accelerate commercialisation of innovative medical device

    🔔French MedTech startup SafeHeal, a medical device innovator transforming colorectal surgery, today announced a €10 million extension of its oversubscribed €35 million Series C financing round.

    đź””NRG Therapeutics, a neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, has closed an oversubscribed ÂŁ50m Series B financing round.

    ===============

    Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.

     

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close